Shares of electroCore, Inc. (NASDAQ:ECOR – Get Free Report) have been given an average recommendation of “Hold” by the five analysts that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $22.00.
Several equities research analysts have weighed in on the company. Zacks Research downgraded electroCore from a “hold” rating to a “strong sell” rating in a report on Wednesday, January 28th. Brookline Capital Acquisition upgraded shares of electroCore to a “strong-buy” rating in a research note on Tuesday, February 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of electroCore in a research note on Monday, December 29th. Wall Street Zen upgraded shares of electroCore from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Finally, HC Wainwright reduced their price objective on shares of electroCore from $25.00 to $18.00 and set a “buy” rating on the stock in a report on Monday, January 26th.
Check Out Our Latest Report on ECOR
Institutional Investors Weigh In On electroCore
electroCore Stock Up 4.7%
Shares of ECOR stock opened at $7.97 on Monday. The firm has a 50 day moving average of $6.20 and a two-hundred day moving average of $5.45. The stock has a market capitalization of $63.76 million, a PE ratio of -4.66 and a beta of 0.48. electroCore has a 52 week low of $4.16 and a 52 week high of $15.68.
About electroCore
electroCore, Inc is a commercial-stage bioelectronic medicine company headquartered in Rockaway, New Jersey. The company specializes in the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies designed to address a variety of neurological and inflammatory conditions. Established in 2006, electroCore has focused its efforts on translating neuromodulation science into a compact, patient-administered treatment device.
The company’s lead product, gammaCore®, is a handheld, battery-powered device that delivers nVNS through the skin to the cervical branch of the vagus nerve.
Further Reading
- Five stocks we like better than electroCore
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.
